Phthalylsulfathiazole

Granulation endpoint determination in high-shear mixer trials for pharmaceutical compositions containing 500 mg anhydrous phthalylsulfathiazole per unit dose is governed by impeller power consumption inflection rather than subjective hand-squeeze assessment. When the active pharmaceutical ingredient is received as a cohesive micronized powder with a Carr’s compressibility index routinely exceeding 35% and a bulk density below 0.35 g/cm³, direct compression on a rotary tablet press operating at 45–60 rpm leads to unacceptable weight variability and capping tendency at pre-compression forces above 3.2 kN. The formulation therefore incorporates 8.0% w/w pregelatinized starch (compliant with USP/NF monograph) and 1.5% w/w colloidal silicon dioxide as a glidant, wet-massed to a target moisture content of 6.5–7.5% using a 10% w/v povidone K30 aqueous binder solution. Wet granules are dried in a fluid-bed processor with inlet air temperature set to 60 °C until loss-on-drying stabilizes at ≤2.0%, then milled through a 1.0 mm screen. Compression is executed on a 27-station tablet press tooled with 13 mm round flat-faced beveled-edge punches, targeting a hardness range of 8–12 kp and a friability limit of ≤1.0% after 100 drops in a Roche friabilator. Disintegration time is verified per USP <701>: no individual tablet exceeds 30 minutes in 900 mL simulated intestinal fluid without enzymes at 37 ± 2 °C. Finished product is released as Phthalylsulfathiazole Tablets USP, 500 mg, in 100-count HDPE bottles with induction-sealed closures. Compliance is maintained under 21 CFR 211 current good manufacturing practice, with batch records referencing USP Phthalylsulfathiazole Tablets monograph for assay limits of 95.0–105.0% of labeled potency and dissolution specification of Q = 75% at 45 minutes in pH 7.4 phosphate buffer using Apparatus II at 75 rpm. Scale-up batches exceeding 300 kg granulation size have shown sensitivity to overwetting within a window of only ±4% of the target binder solution volume, beyond which tablet porosity collapses and disintegration failure occurs.

Carrier Selection and Blend Uniformity Thresholds for 10% Phthalylsulfathiazole Premixes

Production of a 10% w/w medicated feed premix for oral administration to swine and poultry begins with the selection of a lignocellulosic carrier, typically ground corn cob fraction between 300 µm and 800 µm with a water activity below 0.60 to suppress hydrolytic cleavage of the sulfonamide linkage during shelf storage. The active ingredient is pre-blended with the carrier at a 1:3 ratio in a 200 L drum tumbler for 10 minutes before transferring to a 1,500 L double-ribbon mixer where geometric dilution continues until the final active concentration of 100 g/kg is achieved. Blend uniformity sampling uses a stratified thief probe to collect 10 samples from defined zones in the mixer; acceptance requires that the coefficient of variation not exceed 5.0% with all individual assays falling within ±10.0% of the declared content, as prescribed by EU Regulation 2019/4 for medicated feed and aligned with FAMI-QS Code of Practice requirements for feed additive operators. Adding 0.5% w/w mineral oil as a dust suppressant reduces airborne active particulate during bagging but increases the risk of concentration-dependent electrostatic adhesion to mixer walls when relative humidity in the manufacturing bay falls below 30%; facilities operating in this range install active humidity control to maintain 40–55% RH. Each 25 kg bag of premix is labeled with the recommended inclusion rate for complete feed: for growing swine, 1.0–2.0 kg premix per 1,000 kg of finished feed delivers a prophylactic dose equivalent to 100–200 mg active per kg of complete ration; for broiler chickens the inclusion is adjusted to 0.8–1.5 kg per metric tonne during enteric challenge periods. Premix is incorporated via a micro-dosing system positioned after the hammer mill and prior to steam conditioning in the pellet mill, where a conditioning temperature not exceeding 80 °C for 30 seconds is enforced to preserve potency. Terminal product is a 10% Phthalylsulfathiazole Premix packaged in multi-wall paper sacks with polyethylene liner, shipped under a veterinary prescription or feed directive according to the importing jurisdiction’s classification of sulfonamide-containing medicated articles.

Soluble powder formulations designed for continuous metering into poultry house drinking water lines must deliver a completely dispersible, non-flocculating suspension at the point of use while avoiding sedimentation that clogs proportioner diaphragms and nipple drinkers. Particle size reduction of the active ingredient to a volume mean diameter (D[4,3]) below 30 µm by air-jet milling is critical, because any fraction retained on a 75 µm screen risks forming insoluble aggregates under the turbulent but low-shear conditions inside a 1:128 medicator. The carrier matrix is co-spray-dried lactose monohydrate (Ph.Eur. 10.0) blended with 1.0% w/w sodium lauryl sulfate as a wetting agent and 0.2% w/w xanthan gum to provide a weak thixotropic network that retards settling without producing a yield stress exceeding 50 mPa·s at 100 s⁻¹. In a stock solution prepared at 100 g of soluble powder per 4 L of water, the active ingredient concentration is 25 mg/mL at the label claim of 25% w/w phthalylsulfathiazole content. This stock is injected into the drinking water main at a dilution ratio calibrated to achieve a final medicated water concentration of 0.5–1.0 g active per liter for treatment of colibacillosis outbreaks in layers, with the upper limit dictated by palatability aversion observed in controlled intake studies when concentrations exceed 1.2 g/L. Compliance with the Veterinary International Conference on Harmonization (VICH) GL18 guideline for stability testing of veterinary medicinal products dictates that accelerated storage at 40 °C/75% RH for 6 months must not result in a loss of assayed potency greater than 5.0% nor the appearance of the acid hydrolysis product phthalic acid above 0.5%. Equipment cleaning procedures are validated by swab sampling of proportioner intake screens after each batch, with a residue limit of not more than 10 µg/cm² established from a health-based exposure calculation for cross-contamination of non-target species. The terminal product is Phthalylsulfathiazole 25% Soluble Powder, filled into 500 g and 2 kg foil-lined pouches and labelled with species-specific withdrawal periods ranging from 5 days for broilers to 12 days for laying hens not producing eggs for human consumption.

Pellet Durability Factor and Leaching Losses in Extruded Shrimp Feed Containing Phthalylsulfathiazole

Incorporation of phthalylsulfathiazole into extruded sinking pellets for Penaeus vannamei requires precise manipulation of the post-extrusion drying curve because the molecule’s amorphous domains created during high-shear wet extrusion at barrel temperatures between 105 °C and 125 °C increase the effective surface area accessible to water ingress. A feed mill operating a twin-screw extruder with an L/D of 32:1 and a die pressure of 3.5–5.0 MPa will combine fishmeal (25%), soybean meal (30%), wheat flour (20%), and the medicated premix fraction ( 2 kg of 10% phthalylsulfathiazole premix per 1,000 kg dry mash to yield a finished feed concentration of 200 mg/kg) before steam conditioning to 90 °C. The critical parameter is post-extrusion residence time in the horizontal belt dryer: pellets exiting at 18–20% moisture must be dried to 9–10% using staged air temperatures starting at 110 °C in zone one and falling to 70 °C in zone four over a 45-minute cycle, because prolonged exposure above 115 °C while water activity is still high accelerates desulfonation to sulfathiazole with a first-order rate constant approximately 0.012 min⁻¹. Pellet durability index measured on a Holmen tester for 120 seconds must remain above 98.5, otherwise fine generation during pneumatic conveying creates a medicated dust fraction that segregates from the bulk feed and causes under-dosing. Leaching of the active from intact pellets in still seawater at 30 °C and 35 ppt salinity is tested by immersion of 10 g samples for 60 minutes; accepted lots show no more than 15.0% loss of declared active, a specification derived from pond water exchange data and semi-intensive stocking densities. Regulatory oversight in major shrimp-exporting nations requires that medicated feed be manufactured under a HACCP plan recognizing the sulfonamide residue as a chemical hazard, with critical control points set at the premix addition step and the dryer discharge temperature. The final product is a 2.5 mm diameter sinking pellet labeled for the control of bacterial enteritis due to Vibrio spp., distributed in 25 kg woven polypropylene bags with an inner moisture barrier, accompanied by a veterinary prescription where required under FAO Code of Conduct for Responsible Fisheries guidelines for antimicrobial use in aquaculture.

Controlling the oral plasma concentration curve of phthalylsulfathiazole in equine practice is complicated by the compound’s minimal systemic absorption from a healthy equine small intestine; the therapeutic target is a depot concentration within the hindgut lumen sufficient to suppress Enterobacteriaceae without triggering a disbiosis-driven laminitis cascade. Hence, a compounded intragastric paste dosed at 50 mg/kg body weight every 12 hours is manufactured by suspending the micronized active in a thixotropic vehicle composed of 40% v/v fractionated coconut oil and 5.0% w/w hydrogenated castor oil, structured into a shear-thinning paste with a plastic viscosity of 120–180 Pa·s as measured on a Brookfield DV-III+ rheometer with a T-bar spindle at 0.5 rpm. The paste is filled into 30 mL or 60 mL multi-dose oral dosing syringes graduated in 1.0 mL increments, calibrated to deliver 200 mg active per mL of expelled paste. Uniformity of content is verified by assaying 10 syringe aliquots taken at the beginning, middle, and end of the filling run, with acceptance limits of ±15.0% of labeled active per USP <905> for non-aqueous paste dosage forms. Stability protocols stored under 25 °C/60% RH label conditions track the formation of visible oil separation over 24 months; batches developing a supernatant layer exceeding 2.0 mL per syringe are rejected due to erratic dosing during out-of-hand administration. The formulation is considered an extemporaneous compounded preparation under most veterinary practice acts, exempt from full new animal drug approval, but practitioners frequently request a certificate of analysis confirming compliance with a microbial limit of <10² CFU/g total aerobic count and absence of Salmonella spp. per USP <62>. The end-use article is an Equine Intragastric Paste syringe bearing a species-specific “Not for use in horses intended for human consumption” legend, with a mandatory withdrawal interval of 28 days applied under FEI Equine Prohibited Substances List interpretations when competition horses are treated under a valid veterinary exemption.

Does Dry Particle Coating with Hydrophobic Silica Extend Aqueous Suspension Stability in Tropical Distribution Channels?

Paediatric oral suspensions of phthalylsulfathiazole destined for regions classified as Zone IVb climate ( 30 °C/75% RH long-term testing condition per WHO Technical Report Series No. 953) are prepared at a concentration of 100 mg/mL active and packaged in 120 mL amber PET bottles with a child-resistant closure. The suspension base relies on a synergistic combination of microcrystalline cellulose and sodium carboxymethylcellulose (Avicel® RC-591, 1.2% w/v) hydrated in the aqueous phase at 70 °C under a Silverson high-shear rotor-stator mixer at 3,000 rpm for 15 minutes to develop the thixotropic gel structure. Before incorporation, the active ingredient particles undergo high-intensity blending with 0.8% w/w fumed hydrophobic silica (BET surface area 220 m²/g) in a cyclomix reactor operating at 15 m/s tip speed for 6 minutes, a step that deposits a nano-textured coating reducing the polar component of the surface free energy below 25 mJ/m² as confirmed by inverse gas chromatography. The suspension is then de-aerated under vacuum (− 0.8 bar) and passed through a 3-roll mill set to a 20 µm roller gap to break up any soft agglomerates persisting after the coating step. Accelerated settling tests in a LUMiSizer dispersion analyzer at 1,500 rpm and 40 °C predict a mean separation front velocity below 0.8 mm/day over the intended 36-month shelf life, corresponding to acceptable redispersibility after 15 seconds of hand shaking. The product complies with the British Pharmacopoeia monograph for Phthalylsulfathiazole Oral Suspension, which stipulates an assay range of 92.5–107.5% and a pH between 5.0 and 6.5. Distribution to climate zones where cold-chain logistics are interrupted requires real-time thermal exposure data loggers embedded in shipping containers; degradation incidents are triggered by excursions above 48 °C for a cumulative duration of >72 hours, beyond which the dimerization impurity phthalylsulfathiazole-dimer must be quantified by HPLC and confirmed below the 1.0% threshold. End product is a paediatric oral suspension labelled for bacillary dysentery therapy at a dose of 50 mg/kg body weight in divided daily administrations, with an explicit printed caution against use in neonates due to the risk of kernicterus linked to sulfonamide displacement of bilirubin from albumin binding sites.

The use of phthalylsulfathiazole in coccidiosis management programs for domestic rabbits raised on deep litter systems departs from typical prophylactic ionophore protocols in that the drug is delivered not as a feed additive but as a targeted oral drench during the acute intestinal phase of Eimeria spp. infection when bloody diarrhea first appears. A treatment drench is compounded at a strength of 300 mg/mL by dispersing the active in a vehicle of 40% propylene glycol, 5.0% polysorbate 80, and 55% purified water, homogenized at 10,000 rpm using an Ultra-Turrax disperser until a uniform creamy texture is achieved. The dose regimen— 75 mg/kg body weight once daily for 3 consecutive days—requires that the drench be administered via a calibrated dosing gun fitted to a 2 mL syringe, necessitating the formulation’s yield stress be tuned below 10 Pa to allow smooth ejection through an 18-gauge stainless steel dosing needle without clogging. Large-scale cattery and rabbitry operations using the drench operate under written veterinary standard operating procedures that specify a treatment-to-slaughter withdrawal period of 14 days, derived from residue depletion studies in rabbit liver using LC-MS/MS with a limit of detection of 10 µg/kg. Regulatory oversight for minor species applications derives from the U.S. FDA Minor Use/Minor Species (MUMS) designation pathway; although phthalylsulfathiazole lacks an explicit rabbit claim under 21 CFR §520, extra-label use under the Animal Medicinal Drug Use Clarification Act (AMDUCA) is permissible if a valid veterinarian-client-patient relationship exists and an extended withdrawal period is assigned. Finished product is an individual 50 mL amber glass vial labeled as a compounded rabbit oral drench, to be dispensed only with a written prescription and chain-of-custody documentation mandated for sulfonamide residues in food-producing species under EU Regulation 37/2010 Annex Table I.

Published data on the dry granulation of phthalylsulfathiazole via roller compaction for continuous tablet manufacturing remains limited, yet several development reports note that the material exhibits a distinct critical ribbon relative density threshold of 0.70–0.75 when processed on a Chilsonator® IR-220 with smooth rolls and a roll force of 7–10 kN/cm. Ribbons compacted below this threshold generate fines exceeding 35% of the milled granulation mass when passed through a 1.0 mm screen, leading to segregation in downstream tablet press feed frames and cyclic weight variability that is detectable on a checkweigher sampling at 100% line speed. Process analysts have mapped the acceptable operating space using near-infrared monitoring of ribbon porosity inline, and the established set point for maintaining active content uniformity within ±5.0% at a compression speed of 80,000 tablets/hour requires that the ribbon solid fraction be maintained between 0.72 and 0.77. The decision to adopt roller compaction over a conventional wet granulation step is largely driven by the desire to eliminate a terminal drying cycle, thereby reducing energy consumption by approximately 45% per batch based on side-by-side mass balance calculations for a 500 kg scale. Absent a full ICH stability package for this continuous-process variant, manufacturers default to the ICH Q8(R2) quality-by-design framework, lodging the design space in a regulatory filing with a commitment to validate near-infrared probe robustness under at least 3 different ambient humidity scenarios including low (20% RH), mid (45% RH), and high (75% RH). The terminal product remains Phthalylsulfathiazole Tablets USP, with no change to the label-claim strength or container-closure system, but the manufacturing process is designated as continuous direct compression in the ANDA module 3.2.P.3 description.